Arrhythmia

Featured Article

Investigating the Link Between Atrial Fibrillation and Type 2 Diabetes

Investigating the Link Between Atrial Fibrillation and Type 2 Diabetes

Compared with the general population, patients with type 2 diabetes are at a 35% to 60% greater risk for atrial fibrillation.

Latest Features

Investigating the Link Between Atrial Fibrillation and Type 2 Diabetes

Investigating the Link Between Atrial Fibrillation and Type 2 Diabetes

Compared with the general population, patients with type 2 diabetes are at a 35% to 60% greater risk for atrial fibrillation.

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.

Sudden Death in Young Athletes: Screening, Risk Factors, and Prevention

Sudden Death in Young Athletes: Screening, Risk Factors, and Prevention

Evaluating screening and prevention for sudden death in young athletes.

"Lone" Atrial Fibrillation: Lifestyle Management and Hybrid Procedures

"Lone" Atrial Fibrillation: Lifestyle Management and Hybrid Procedures

Optimal treatment strategies for lone atrial fibrillation have been unclear, but more technological advances and understanding of disease are propelling researchers forward.

"Lone" Atrial Fibrillation: Finding Optimal Treatment Strategies

"Lone" Atrial Fibrillation: Finding Optimal Treatment Strategies

Optimal treatment strategies for lone atrial fibrillation have been unclear, but more technological advances and understanding of disease are propelling researchers forward.

Atrial Fibrillation: Updates in Screening, Surgical Ablation, and Anticoagulation Use

Atrial Fibrillation: Updates in Screening, Surgical Ablation, and Anticoagulation Use

Anticoagulation under- and overdoing can be problematic in patients with atrial fibrillation.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Weighing Benefits and Risks of Anticoagulation in the Elderly

Weighing Benefits and Risks of Anticoagulation in the Elderly

Determining which patients who have atrial fibrillation should receive anticoagulation therapy for stroke prophylaxis can be challenging.

Oral Anticoagulants After Intracranial Hemorrhage Reduced Mortality Risk in Afib

Oral Anticoagulants After Intracranial Hemorrhage Reduced Mortality Risk in Afib

A declining trend in ischemic events was associated with oral anticoagulant therapy after intracranial hemorrhage.

Premature Ventricle Contractions in Heart Failure: A Closer Examination

Premature Ventricle Contractions in Heart Failure: A Closer Examination

A primer on premature ventricle contractions with commentary from 2 arrhythmic/heart failure experts.

Latest News

Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?

Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?

Several randomized controlled trials are underway to confirm the safety and efficacy of early vs late initiation of direct oral anticoagulants in ischemic stroke associated with atrial fibrillation.

Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure

Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure

Catheter ablation is superior to drug therapy in improving all-cause mortality, LVEF, 6-minute walk test distance, VO2max, and quality of life in patients with heart failure.

Should CHA2DS2-VASc Be Reassessed More Frequently to Improve Stroke Prevention in Afib?

Should CHA2DS2-VASc Be Reassessed More Frequently to Improve Stroke Prevention in Afib?

These results suggest that CHA2DS2-VASc scores should be continually reassessed, perhaps annually, in patients with atrial fibrillation.

FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa

FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa

Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.

Do More Aggressive Periprocedural Antibiotic Regimens Reduce Risk of Device-Related Infections?

Do More Aggressive Periprocedural Antibiotic Regimens Reduce Risk of Device-Related Infections?

The clinical effectiveness of incremental periprocedural antibiotics for patients receiving cardiac implantable electronic devices was examined.

Reversal of Warfarin-Associated Bleeding With 4F-PCC Examined in Obese Patients

Reversal of Warfarin-Associated Bleeding With 4F-PCC Examined in Obese Patients

To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted (N=28) vs actual body weight (N=50).

COPD May Predict Mortality in Ventricular Tachyarrhythmias, Sudden Cardiac Arrest

COPD May Predict Mortality in Ventricular Tachyarrhythmias, Sudden Cardiac Arrest

The presence of COPD is linked to higher all-cause mortality and cardiac death at 24 hours in high-risk patients who present with ventricular tachyarrhythmias and sudden cardiac arrest.

High Free T4 Levels Within Reference Range Associated With Atrial Fibrillation

High Free T4 Levels Within Reference Range Associated With Atrial Fibrillation

Higher levels of free T4 that remain within the reference range are associated with a greater prevalence and incidence of atrial fibrillation.

Vitamin D Plus Calcium Supplementation May Not Modify Atrial Fibrillation Risk

Vitamin D Plus Calcium Supplementation May Not Modify Atrial Fibrillation Risk

Baseline serum 25(OH)D level was not predictive of long-term incident atrial fibrillation risk.

Rivaroxaban Has Positive Risk-Benefit Profile for Non-Valvular Atrial Fibrillation

Rivaroxaban Has Positive Risk-Benefit Profile for Non-Valvular Atrial Fibrillation

Rivaroxaban given at doses of both 20mg and 15mg may have an improved bleeding risk profile compared with vitamin K antagonists.

Sign Up for Free e-Newsletters